Elan Regulatory Holdings

Elan Regulatory Holdings is a subsidiary entity of Perrigo, originally part of the Elan Corporation, a major Irish neuroscience-focused biotechnology company. The entity serves as a holding company for various intellectual property assets and regulatory filings associated with the legacy Elan portfolio, most notably the royalty interests in the multiple sclerosis blockbuster drug Tysabri (natalizumab). Following the acquisition of Elan by Perrigo in 2013, this holding structure manages the financial and regulatory aspects of the acquired pharmaceutical assets. Its primary business function is the management of high-value pharmaceutical royalties and legacy biotech investments within the Perrigo corporate framework.